


REMARKS

This preliminary amendment is being submitted in a continuation of application Serial No. 09722,784. New claims 55 to 60 are fully supported by the specification and the claims as originally filed in the parent case, more specifically at page 20, lines 18 to 27, where it is disclosed that motility regulation is provided where both tegaserod and proton pump inhibitors are co-administered. No new matter had been added by the present preliminary amendment. An early and favorable action on the merits is respectfully requested.

Respectfully submitted,



David E. Wildman
Attorney for Applicants
Reg. No. 40,226

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7954

Date: November 6, 2003